Skip to main content

Advertisement

SpringerLink
Log in

Change in lifestyle behaviors and medication use after a diagnosis of ductal carcinoma in situ

  • Epidemiology
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Women with ductal carcinoma in situ (DCIS) of the breast represent a growing cancer survivor population with a diagnosis of uncertain malignant potential. These survivors face an absence of scientific guidelines regarding lifestyle changes that can help to prevent a breast cancer recurrence. In this first report from the Wisconsin In Situ Cohort (WISC) study, we examine how women are currently changing their lifestyle behaviors and medication use following a diagnosis of DCIS. At study entry (1997–2006), 1,959 subjects (78% of eligible) with DCIS were identified from the Wisconsin cancer registry and administered an interview assessing behaviors prior to diagnosis. Follow-up interviews were completed every 2 years after the initial interview, beginning in 2003 and continuing through 2006. After adjusting for age and calendar year, women were 2.2 kg (95% CI 1.4, 3.0) heavier, 35% (95% CI 20, 47) less likely to be a smoker, 19% (95% CI −1, 43) more likely to use non-steroidal anti-inflammatory drugs, and 57% (95% CI 26, 95) more likely to use antidepressants after a DCIS diagnosis compared to 1 year prior to diagnosis. Use of postmenopausal hormones decreased sharply (OR = 0.06; 95% CI 0.04, 0.09) following a DCIS diagnosis. These findings indicate that women make substantial changes in their behaviors after a DCIS diagnosis. This cohort will be further monitored to evaluate the association between these behaviors and health outcomes following DCIS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Silverstein MJ, Baril NB (2002) In situ carcinoma of the breast. In: Donegan WL, Spratt JS (eds) Cancer of the breast, 5th edn. Saunders, Philadelphia

    Google Scholar 

  2. Sprague BL, Trentham-Dietz A (2010) In situ breast cancer. In: Li CI (ed) Breast cancer epidemiology. Springer, New York, pp 47–72

    Chapter  Google Scholar 

  3. Sprague BL, Trentham-Dietz A (2009) Prevalence of breast carcinoma in situ in the United States. JAMA 302(8):846–848

    Article  CAS  PubMed  Google Scholar 

  4. Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM (2004) Ductal carcinoma in situ of the breast. N Engl J Med 350(14):1430–1441

    Article  CAS  PubMed  Google Scholar 

  5. Rakovitch E, Franssen E, Kim J et al (2003) A comparison of risk perception and psychological morbidity in women with ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res Treat 77(3):285–293

    Article  PubMed  Google Scholar 

  6. Ernster VL, Barclay J, Kerlikowske K, Wilkie H, Ballard-Barbash R (2000) Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med 160(7):953–958

    Article  CAS  PubMed  Google Scholar 

  7. Warnberg F, Yuen J, Holmberg L (2000) Risk of subsequent invasive breast cancer after breast carcinoma in situ. Lancet 355(9205):724–725

    Article  CAS  PubMed  Google Scholar 

  8. Boyages J, Delaney G, Taylor R (1999) Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Cancer 85(3):616–628

    Article  CAS  PubMed  Google Scholar 

  9. Kerlikowske K, Molinaro A, Cha I et al (2003) Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst 95(22):1692–1702

    PubMed  Google Scholar 

  10. Li CI, Malone KE, Saltzman BS, Daling JR (2006) Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988–2001. Cancer 106(10):2104–2112

    Article  PubMed  Google Scholar 

  11. Habel LA, Daling JR, Newcomb PA et al (1998) Risk of recurrence after ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 7(8):689–696

    CAS  PubMed  Google Scholar 

  12. Norman SA, Potashnik SL, Galantino ML et al (2007) Modifiable risk factors for breast cancer recurrence: what can we tell survivors? J Womens Health (Larchmt) 16(2):177–190

    Article  Google Scholar 

  13. van Gestel YR, Voogd AC, Vingerhoets AJ et al (2007) A comparison of quality of life, disease impact and risk perception in women with invasive breast cancer and ductal carcinoma in situ. Eur J Cancer 43(3):549–556

    Article  PubMed  Google Scholar 

  14. Partridge A, Adloff K, Blood E et al (2008) Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study. J Natl Cancer Inst 100(4):243–251

    Article  PubMed  Google Scholar 

  15. Nichols HB, Trentham-Dietz A, Egan KM et al (2007) Oral contraceptive use and risk of breast carcinoma in situ. Cancer Epidemiol Biomarkers Prev 16(11):2262–2268

    Article  CAS  PubMed  Google Scholar 

  16. Trentham-Dietz A, Nichols HB, Egan KM et al (2007) Cigarette smoking and risk of breast carcinoma in situ. Epidemiology 18(5):629–638

    Article  PubMed  Google Scholar 

  17. Fritz A, Percy C, Jack A et al (eds) (2000) International classification of diseases for oncology, 3rd edn. World Health Organization, Geneva

    Google Scholar 

  18. Armstrong BK, White E, Saracci R (1992) Principles of exposure measurement in epidemiology, vol 21. Oxford University Press, Oxford

    Google Scholar 

  19. Sprague BL, Trentham-Dietz A, Newcomb PA et al (2007) Lifetime recreational and occupational physical activity and risk of in situ and invasive breast cancer. Cancer Epidemiol Biomarkers Prev 16(2):236–243

    Article  PubMed  Google Scholar 

  20. Newcomb PA, Titus-Ernstoff L, Egan KM et al (2002) Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev 11(7):593–600

    CAS  PubMed  Google Scholar 

  21. Palta M (2003) Quantitative methods in population health; extensions of ordinary regression. Wiley, Hoboken

    Google Scholar 

  22. Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333

    Article  CAS  PubMed  Google Scholar 

  23. Irwin ML, McTiernan A, Baumgartner RN et al (2005) Changes in body fat and weight after a breast cancer diagnosis: influence of demographic, prognostic, and lifestyle factors. J Clin Oncol 23(4):774–782

    Article  PubMed  Google Scholar 

  24. Caan B, Sternfeld B, Gunderson E et al (2005) Life after cancer epidemiology (LACE) study: a cohort of early stage breast cancer survivors (United States). Cancer Causes Control 16(5):545–556

    Article  PubMed  Google Scholar 

  25. Saquib N, Flatt SW, Natarajan L et al (2007) Weight gain and recovery of pre-cancer weight after breast cancer treatments: evidence from the women’s healthy eating and living (WHEL) study. Breast Cancer Res Treat 105(2):177–186

    Article  PubMed  Google Scholar 

  26. Hoskin PJ, Ashley S, Yarnold JR (1992) Weight gain after primary surgery for breast cancer—effect of tamoxifen. Breast Cancer Res Treat 22(2):129–132

    Article  CAS  PubMed  Google Scholar 

  27. Ingle JN, Twito DI, Schaid DJ et al (1991) Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis. Cancer 67(4):886–891

    Article  CAS  PubMed  Google Scholar 

  28. Fisher B, Costantino J, Redmond C et al (1989) A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320(8):479–484

    Article  CAS  PubMed  Google Scholar 

  29. Grey AB, Stapleton JP, Evans MC, Reid IR (1995) The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab 80(11):3191–3195

    Article  CAS  PubMed  Google Scholar 

  30. Demark-Wahnefried W, Rimer BK, Winer EP (1997) Weight gain in women diagnosed with breast cancer. J Am Diet Assoc 97(5):519–526, 529; quiz 527-518

    Google Scholar 

  31. Irwin ML, Crumley D, McTiernan A et al (2003) Physical activity levels before and after a diagnosis of breast carcinoma: the health, eating, activity, and lifestyle (HEAL) study. Cancer 97(7):1746–1757

    Article  PubMed  Google Scholar 

  32. Patterson RE, Neuhouser ML, Hedderson MM et al (2003) Changes in diet, physical activity, and supplement use among adults diagnosed with cancer. J Am Diet Assoc 103(3):323–328

    PubMed  Google Scholar 

  33. Ligibel JA, Partridge A, Giobbie-Hurder A et al (2009) Physical activity behaviors in women with newly diagnosed ductal carcinoma-in situ. Ann Surg Oncol 16(1):106–112

    Article  PubMed  Google Scholar 

  34. Thomson CA, Flatt SW, Rock CL et al (2002) Increased fruit, vegetable and fiber intake and lower fat intake reported among women previously treated for invasive breast cancer. J Am Diet Assoc 102(6):801–808

    Article  PubMed  Google Scholar 

  35. Maunsell E, Drolet M, Brisson J, Robert J, Deschenes L (2002) Dietary change after breast cancer: extent, predictors, and relation with psychological distress. J Clin Oncol 20(4):1017–1025

    Article  PubMed  Google Scholar 

  36. Wayne SJ, Lopez ST, Butler LM et al (2004) Changes in dietary intake after diagnosis of breast cancer. J Am Diet Assoc 104(10):1561–1568

    Article  PubMed  Google Scholar 

  37. Holmes MD, Murin S, Chen WY et al (2007) Smoking and survival after breast cancer diagnosis. Int J Cancer 120(12):2672–2677

    Article  CAS  PubMed  Google Scholar 

  38. Hersh AL, Stefanick ML, Stafford RS (2004) National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 291(1):47–53

    Article  CAS  PubMed  Google Scholar 

  39. Kwan ML, Habel LA, Slattery ML, Caan B (2007) NSAIDs and breast cancer recurrence in a prospective cohort study. Cancer Causes Control 18(6):613–620

    Article  PubMed  Google Scholar 

  40. Meeske K, Smith AW, Alfano CM et al (2007) Fatigue in breast cancer survivors two to five years post diagnosis: a HEAL study report. Qual Life Res 16(6):947–960

    Article  PubMed  Google Scholar 

  41. Chubak J, Buist DS, Boudreau DM et al (2008) Breast cancer recurrence risk in relation to antidepressant use after diagnosis. Breast Cancer Res Treat 112(1):123–132

    Article  CAS  PubMed  Google Scholar 

  42. Massie MJ (2004) Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr 32:57–71

    Article  PubMed  Google Scholar 

  43. Kroenke CH, Chen WY, Rosner B, Holmes MD (2005) Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol 23(7):1370–1378

    Article  PubMed  Google Scholar 

  44. Holmberg L, Anderson H (2004) HABITS (hormonal replacement therapy after breast cancer—is it safe?), a randomised comparison: trial stopped. Lancet 363(9407):453–455

    Article  CAS  PubMed  Google Scholar 

  45. Loprinzi CL, Wolf SL, Barton DL, Laack NN (2008) Symptom management in premenopausal patients with breast cancer. Lancet Oncol 9(10):993–1001

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the National Institutes of Health (CA67264 and CA47147). Dr. Sprague is supported by a fellowship from the Prevent Cancer Foundation and the American Society of Preventive Oncology. We are grateful to Drs. Ronald Gangnon, Henry Anderson, Patrick L. Remington, Kathleen Egan, and Linda Titus-Ernstoff for study-related advice; Laura Stephenson and the staff of the Wisconsin Cancer Reporting System; and WISC study staff including Julie McGregor, Kathy Peck, Mary Pankratz, Linda Haskins, and Jerry Phipps, along with the study interviewers for assistance with data collection. We are especially grateful to the study participants, whose generosity made this research possible.

Author information

Authors and Affiliations

  1. Department of Population Health Sciences, University of Wisconsin-Madison, Madison, WI, 53726, USA

    Brian L. Sprague & Amy Trentham-Dietz

  2. University of Wisconsin Carbone Comprehensive Cancer Center, 610 Walnut St., WARF Room 307, Madison, WI, 53726, USA

    Brian L. Sprague, Amy Trentham-Dietz, Hazel B. Nichols, John M. Hampton & Polly A. Newcomb

  3. Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA

    Polly A. Newcomb

Authors
  1. Brian L. Sprague
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amy Trentham-Dietz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hazel B. Nichols
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John M. Hampton
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Polly A. Newcomb
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Brian L. Sprague.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sprague, B.L., Trentham-Dietz, A., Nichols, H.B. et al. Change in lifestyle behaviors and medication use after a diagnosis of ductal carcinoma in situ. Breast Cancer Res Treat 124, 487–495 (2010). https://doi.org/10.1007/s10549-010-0869-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-010-0869-0

Keywords

Search

Navigation